Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
133 hedge funds and large institutions have $312M invested in Catalyst Pharmaceutical in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 17 closing their positions.
207% more call options, than puts
Call options by funds: $834K | Put options by funds: $272K
40% more capital invested
Capital invested by funds: $222M → $312M (+$89.5M)
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
0.96% more ownership
Funds ownership: 64.23% → 65.2% (+0.96%)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1% less funds holding
Funds holding: 135 → 133 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$11.2M |
| 2 |
RA
Royce & Associates
New York
|
+$3.36M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.18M |
| 4 |
Citigroup
New York
|
+$2.59M |
| 5 |
State Board of Administration of Florida Retirement System
Tallahassee,
Florida
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$7.15M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$5.84M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$4.51M |
| 4 |
Man Group
London,
United Kingdom
|
-$2.5M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$1.21M |
CPRX Hedge Fund Activity: Q1 2021 in Review
133 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2021, worth a combined $312M — up 40% from $222M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CPRX and 16 opened new positions — a net loss of 1 holder — while 44 trimmed existing stakes and 50 added.
The largest buyer was State Street, adding an estimated $11.2M. The largest seller was Goldman Sachs, cutting an estimated $7.15M.
- 133 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2021, down from 135 in Q4 2020.
- Funds reported $312M of Catalyst Pharmaceutical stock for Q1 2021, up 40% quarter-over-quarter.
- 16 funds opened new Catalyst Pharmaceutical positions in Q1 2021 and 17 closed out, a net change of -1 holder.
- The largest Catalyst Pharmaceutical buyer in Q1 2021 was State Street, an estimated $11.2M added.
- The largest Catalyst Pharmaceutical seller in Q1 2021 was Goldman Sachs, an estimated $7.15M sold.
Based on aggregated 13F filings for Q1 2021.